Blurbs

Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Boston Scientific (BSX) and Bristol Myers (BMY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Align Tech (ALGNResearch Report), Boston Scientific (BSXResearch Report) and Bristol Myers (BMYResearch Report).

Align Tech (ALGN)

In a report released today, Erin Wright from Morgan Stanley maintained a Buy rating on Align Tech, with a price target of $402.00. The company’s shares closed last Thursday at $279.99, close to its 52-week low of $225.86.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 17.0% and a 66.1% success rate. Wright covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, DENTSPLY SIRONA, and SmileDirectClub.

Currently, the analyst consensus on Align Tech is a Moderate Buy with an average price target of $344.17, a 27.2% upside from current levels. In a report issued on July 14, Stifel Nicolaus also maintained a Buy rating on the stock with a $375.00 price target.

See today’s best-performing stocks on TipRanks >>

Boston Scientific (BSX)

Morgan Stanley analyst Cecilia Furlong maintained a Buy rating on Boston Scientific today and set a price target of $49.00. The company’s shares closed last Thursday at $40.96.

According to TipRanks.com, Furlong is a 5-star analyst with an average return of 20.0% and a 52.2% success rate. Furlong covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Bausch + Lomb Corporation, and Zimmer Biomet Holdings.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific with a $47.18 average price target, a 17.2% upside from current levels. In a report issued on July 20, Truist Financial also maintained a Buy rating on the stock with a $45.00 price target.

Bristol Myers (BMY)

In a report released today, Terence Flynn from Morgan Stanley maintained a Sell rating on Bristol Myers, with a price target of $61.00. The company’s shares closed last Thursday at $74.57.

According to TipRanks.com, Flynn is a 5-star analyst with an average return of 12.9% and a 62.5% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Johnson & Johnson, and Merck & Company.

Currently, the analyst consensus on Bristol Myers is a Moderate Buy with an average price target of $78.57.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos